Dermata Therapeutics, Inc.DRMANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank27
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P27
Within normal range
vs 2Y Ago
-2.4x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -18.36% |
| Q2 2025 | -51.77% |
| Q1 2025 | -41.57% |
| Q4 2024 | -8.70% |
| Q3 2024 | 19.52% |
| Q2 2024 | 25.51% |
| Q1 2024 | 41.03% |
| Q4 2023 | 25.70% |
| Q3 2023 | 7.63% |
| Q2 2023 | -29.66% |
| Q1 2023 | 34.10% |
| Q4 2022 | -42.74% |
| Q3 2022 | -3.70% |
| Q2 2022 | 1.07% |
| Q1 2022 | 43.55% |
| Q4 2021 | 39.01% |
| Q3 2021 | -7.77% |
| Q2 2021 | 27.42% |
| Q1 2021 | 495.45% |
| Q4 2020 | -5.12% |
| Q3 2020 | -70.76% |
| Q2 2020 | -57.14% |
| Q1 2020 | 0.00% |